PMID- 17722708
OWN - NLM
STAT- MEDLINE
DCOM- 20080129
LR  - 20190608
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
VI  - 68
IP  - 2
DP  - 2007 Aug
TI  - Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis 
      patients on calcium carbonate therapy.
PG  - 93-8
AB  - AIMS: Histamine H2 receptor antagonists (HRA) or proton pump inhibitors (PPI) are 
      frequently administered to patients on hemodialysis, because their intestinal 
      mucosa is fragile. Although three studies have indicated that concomitant HRA 
      administration causes a decrease in the binding of phosphate by calcium 
      carbonate, the HRA doses tested in these studies were 2-4 times higher than the 
      recommended dose for hemodialysis patients. In addition, it remains unclear 
      whether PPI therapy affects serum phosphate levels in hemodialysis patients 
      taking calcium carbonate. Accordingly, the aim of this study was to evaluate the 
      influence of lansoprazole and the recommended dose of famotidine on serum 
      phosphate and calcium levels in hemodialysis patients. METHODS: The study 
      included 115 hemodialysis patients who were taking calcium carbonate and who were 
      also treated with either famotidine (10 mg/day) or lansoprazole (30 mg/day). 
      Changes of the mean serum phosphate and calcium levels over 2 months before and 
      after the start of famotidine or lansoprazole therapy were compared. The same 
      parameters were also compared when famotidine was switched to lansoprazole. 
      RESULTS: The mean serum phosphate level increased significantly after 
      administration of either famotidine or lansoprazole (by 6.6 +/- 21.9% or 13.0 +/- 
      26.3%, p = 0.032 and p = 0.029, respectively). The mean serum calcium level was 
      unchanged after administration of famotidine, but showed a significant decrease 
      after administration of lansoprazole (by 3.44 +/- 7.73%, p = 0.013). Therefore, 
      the calcium x phosphorus product was significantly increased by administration of 
      famotidine, but not by administration of lansoprazole (6.68 +/- 23.37% and 8.73 
      +/- 27.41%, p = 0.046 and p = 0.251, respectively). When famotidine was switched 
      to lansoprazole, the serum phosophate level did not change, but serum calcium 
      decreased significantly by 3.8 +/- 13.0% (p = 0.0006). CONCLUSION: Not only 
      administration of 20 mg/ day of famotidine as previously reported, but also 10 
      mg/day of this drug (the recommended dose for hemodialysis patients) caused a 
      significant increase of serum phosphate in patients taking calcium carbonate. 
      PPIs have been reported to show no effect on the serum phosphate level, but 30 
      mg/day of lansoprazole also caused a significant increase of serum phosphate in 
      patients taking calcium carbonate.
FAU - Matsunaga, C
AU  - Matsunaga C
AD  - Department of Pharmacy Services, Shirasagi Hospital, Osaka, Japan.
FAU - Izumi, S
AU  - Izumi S
FAU - Furukubo, T
AU  - Furukubo T
FAU - Satoh, M
AU  - Satoh M
FAU - Yamakawa, T
AU  - Yamakawa T
FAU - Uchida, T
AU  - Uchida T
FAU - Kadowaki, D
AU  - Kadowaki D
FAU - Hirata, S
AU  - Hirata S
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 27YLU75U4W (Phosphorus)
RN  - 5QZO15J2Z8 (Famotidine)
RN  - H0G9379FGK (Calcium Carbonate)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*pharmacology
MH  - Calcium Carbonate/*therapeutic use
MH  - Famotidine/*pharmacology
MH  - Female
MH  - Histamine H2 Antagonists/*pharmacology
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Phosphorus/*blood
MH  - *Proton Pump Inhibitors
MH  - *Renal Dialysis
EDAT- 2007/08/29 09:00
MHDA- 2008/01/30 09:00
CRDT- 2007/08/29 09:00
PHST- 2007/08/29 09:00 [pubmed]
PHST- 2008/01/30 09:00 [medline]
PHST- 2007/08/29 09:00 [entrez]
AID - 10.5414/cnp68093 [doi]
PST - ppublish
SO  - Clin Nephrol. 2007 Aug;68(2):93-8. doi: 10.5414/cnp68093.